Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -1.98
- Piotroski Score 2.00
- Grade Market Outperform
- Symbol (ELEV)
- Company Elevation Oncology, Inc.
- Price $0.62
- Changes Percentage (-4.52%)
- Change -$0.03
- Day Low $0.61
- Day High $0.67
- Year High $5.83
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/31/2024
- Fiscal Year End N/A
- Average Stock Price Target $9.00
- High Stock Price Target $10.00
- Low Stock Price Target $8.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.85
- Trailing P/E Ratio -4.15
- Forward P/E Ratio -4.15
- P/E Growth -4.15
- Net Income $-45,704,000
Income Statement
Quarterly
Annual
Latest News of ELEV
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Couche-Tard asks 7-Eleven owner for talks after $38.5 billion offer rejected
By Scott Murdoch and Kane Wu(Reuters) -Canada's Alimentation Couche-Tard said on Sunday it was willing to engage in confidential discussions with Japanese retail giant Seven & i Holdings on its $3...
By Reuters | 1 hour ago -
Jeff Goldblum's big 'Jurassic Park' scene "changed at eleventh hour"
Jeff Goldblum shared how an iconic scene in Jurassic Park was altered last minute with Steven Spielberg's approval. The actor praised Spielberg's creativity and flexibility in making changes, leading ...
By Newsweek | 2 days ago -
7-Eleven Rejects Takeover Bid from Big Canadian Chain
The owner of 7-Eleven rejected a buyout offer from a Canadian convenience store giant, indicating a strategic move to boost shareholder value....
By The New York Times | 3 days ago
